The use of Imatinib mesylate in Nigerians with chronic myeloid leukemia
Prof. Muheez A. Durosinmi1, Prof. Julius O. Faluyi2, Dr. Anthony A. Oyekunle1, Dr. Lateef Salawu1, Dr. Ismail A. Adediran1, Dr. Norah O. Akinola1, Oluwakemi O. Bamgbade3, Dr. Charles C. Okanny4, Dr. Sulaiman Akanmu4, Dr. Oche P. Ogbe5, Dr. Tambi T. Wakama5, Dr. Chijoke A. Nwauche6, Dr. Matthew E. Enosolease7, Dr. Daye N.K. Halim7, Dr. Godwin N. Bazuaye7, Dr. Chide E. Okocha8, Dr. J. A. Olaniyi9, Dr. Titi S. Akingbola9, Dr. Victor O. Mabayoje10, Dr. Ajani A. Raji10, Dr. Aisha Mamman11, Dr. Aisha Kuliya-Gwarzo12, Dr. Obike G. Ibegbulam13, Dr. Sunday Ocheni13, Dr. Yohanna Tanko14, Dr. Oladimeji P. Arewa1, Dr. Rahman A.A. Bolarinwa1, Dr. Davidson O. Kassim1, Dr. Mohammed A. Ndakotsu1, Dr. Omotilewa A. Amusu15, Prof. O. O. Akinyanju16
1Department of Haematology, Obafemi Awolowo University Teaching Hospital Complex, Ile-Ife, Nigeria; 2Department of Botany, Obafemi Awolowo University, Ile-Ife, Nigeria; 3Department of Pharmacy, Obafemi Awolowo University Teaching Hospitals Complex, Ile-Ife, Nigeria; 4Department of Haematology, University of Lagos, Nigeria; 5Department of Haematology, National Hospital, Abuja, Nigeria; 6Department of Haematology, University of Port-Harcourt, Port-Harcourt, Nigeria; 7Department of Haematology, University of Benin, Nigeria; 8Department of Haematology, Nnamdi Azikiwe University, Nnewi, Nigeria; 9Department of Haematology, University College Hospital, Ibadan, Nigeria; 10Department of Haematology, Ladoke Akintola University of Technology, Osogbo, Nigeria; 11Department of Haematology, Ahmadu Bello University, Zaria, Nigeria, 12Department of Haematology, Bayero University, Kano, Nigeria; 13Department of Haematology, University of Nigeria, Enugu, Nigeria; 14Department of Haematology, Gwagwalada Specialist Hospital, Abuja, Nigeria; 15Department of Haematology, Army Reference Hospital, Lagos, Nigeria; 16Asaju Medical Clinic, Victoria Island, Lagos, Nigeria
Accepted 21 November 2008
Published 15 December 2008
To assess response and toxicity to Imatinib mesylate (Glivec) in Nigerian Patients with chronic myeloid leukemia.
From August 2003 to August 2007, 98 consecutive, consenting patients, 56 (57%) males and 42 (43%) females, median age 36 years (range, 11-65 years) diagnosed with CML, irrespective of disease phase received Imatinib at a dose of 300-600mg/day at the OAU Teaching Hospitals, Nigeria. Response to therapy was assessed by clinical, haematological and cytogenetic parameters. Blood counts were checked every two weeks in the first three months of therapy. Chromosome analysis was repeated sixth monthly. Overall survival (OS) and frequency of complete or major cytogenetic remission (CCR/MCR) were evaluated.
Complete haematologic remission was achieved in 64% and 83% of patients at one and three months, respectively. With a median follow-up of 25 months, the rates of CCR and MCR were 59% and 35% respectively. At 12 months of follow-up, OS and progression- free survival (PFS) were 96% and 91%, respectively. Achievement of CR at six months was associated with significantly better survival (p = 0.043).
Compared to treatment outcome with conventional chemotherapy and alpha interferon, as previously used in Nigeria, the results obtained with this regimen has established Imatinib as the first-line treatment strategy in patients with CML, as it is in other populations, with minimal morbidity.
Imatinib mesylate, cytogenetic remission, nigeria, chronic myeloid leukemia
Chronic myeloid leukaemia (CML) has an annual worldwide incidence of 1/100,000, with a male: female ratio of 1.5:1. The incidence rises slowly with age to reach a median of about 60 years . The median age of patients with CML in Nigeria and other African countries with a similar demographic pattern is 38 years [2, 3]. Fleming and Menendez reported that more native African patients under age 40 years suffer from CML than any other group in the world; this differential age incidence pattern of CML is believed to be due to the age distribution of African populations rather than any inherent biological characteristic . In the USA however, the incidence of CML in the age group under 70 years is higher among the African-Americans than among any other racial/ethnic groups . It is probable that a combination of environment and as yet unknown biological factors may account for the differential age incidence pattern of CML between the Blacks and the other races in USA.
The advent of Imatinib, an orally available, small molecule signal transduction inhibitor (STI) that specifically targets protein tyrosine kinases (TKIs), in particular, the CML-related bcr-abl, has led to radical changes in the management of CML following the publication of several studies that confirmed superior clinical, haematologic and cytogenetic remissions when the drug was compared to IFN-α and ara-C in all phases of the disease [6-9]. Imatinib has become the first-line therapy for CML in the world, allogeneic stem cell transplantation now being reserved mainly for younger patients with poor-risk disease or for those who are resistant to Imatinib and/ or second generation TKIs [8, 9]. With the availability of free Imatinib Mesylate in resource-poor countries (through donation from the Glivec international patient-assistance program [GIPAP]; www.maxaid.org), this drug has also become the first-line therapy for CML in Nigeria; a great relief for patients in resource-limited countries.
This report describes the results for patients with newly diagnosed CML in diverse phases of the disease that were treated with Imatinib.
Patients and Methods
Between August 2003 and August 2007, a total of 98 consenting adults and children, who had been diagnosed with CML, were commenced on Imatinib as part of the ongoing GIPAP treatment programme at the Obafemi Awolowo University Teaching Hospitals Complex (OAUTHC), Ile-Ife, Nigeria. Eighty-four patients had been exposed to previous single-agent chemotherapy comprising: hydroxyurea (n = 79), busulphan (n = 5) and IFN-alfa (n = 5). Five patients had previously received concurrent multiple chemotherapeutic agents, including Cyclophosphamide, Oncovin, ara-C and prednisolone (COAP; n = 4) and Doxorubicin and ara-c (DA; n = 1). Participants were drawn from all parts of Nigeria. The diagnosis of CML was made according to the WHO standard clinical, haematologic and cytogenetic criteria , which has also been applied to the staging of the diseases in Imatinib era .
Chromosome analysis was done using cultured bone marrow aspirate samples; Philadelphia chromosome was estimated from at least 20 metaphases and the proportion of Ph+ cells was noted for each patient.
Patients in chronic phase received oral Imatinib: 400mg daily. Those in the accelerated or blastic phase received 600mg daily. Imatinib was continued for as long as there was evidence of continued benefit from therapy. Allopurinol (300 mg daily) was given until leucocyte count fell below 20 x 109/L. Patients with hyperleucocytosis (leucocyte count > 100 x 109/L), and on hydroxyurea, were continued on the latter for another 1-3 weeks, with monitoring of the full blood count before final withdrawal of the drug, when the white cell count fell to less than 100 x 109/L.
In individuals with severe Imatinib-induced myelosuppression, the drug was withheld until the neutrophils rose to 1.5 x 109/L and the platelets to at least 75 x 109/L. Patients with recurrent, therapy-induced myelosuppression had the Imatinib dose reduced to 300mg daily until blood counts normalised (minimum dose for therapeutic blood levels in adults). However, if the myelosuppression was related to blastic transformation, Imatinib was continued with appropriate supportive therapy being given.
Response to therapy was assessed by clinical, haematologic and cytogenetic parameters as recommended by the expert panel of the European LeukemiaNet . Clinical examination and full blood count monitoring were performed every 1-2 weeks for the first three months, until the blood count became stable, or until remission was achieved. Thereafter, patients were monitored every three months. Serum chemistry and cytogenetic analyses were evaluated every six months.
Previously published definitions of CP, AP and BP were used [10, 11]. Overall survival (OS) was the primary end-point and was defined as the interval between the date of commencement of Imatinib and the date of death or loss to follow-up. Secondary end-points were time to complete haematologic remission (CHR) and/or complete cytogenetic remission (CCR). CHR was defined as restoration of a normal blood count, with absence of blasts or promyelocytes, extramedullary deposits, or other signs of the disease. Cytogenetic response was checked every 6 months, by counting proportions of Ph+ cells from among not less than 20 metaphases, whilst definitions of complete, major, minor and no cytogenetic response (CCR (0% Ph+), MCR (1-34% Ph+), mnCR (35-90 Ph+), and NCR (> 90% Ph+) and those for complete or major molecular response (CMR, MMR) were as previously described .
Figure 1. Overall survival of patients according to attainment of complete cytogenetic remission (CCR) at 6 months
This study was conducted according to the declaration of Helsinki concerning patients' rights and confidentiality. Approval for the study was obtained from the OAUTHC ethical committee. All patients or their parents (in the case of minors) gave written informed consent.
The study is ongoing but for the purpose of this analysis, August 31st 2007 was taken as the cut-off, this being the date on which the first patient has been followed-up for 48 months. Analyses of OS and PFS were performed using the Kaplan-Meier method, by "intention-to-treat". Differences between subgroups of patients receiving Imatinib were analysed using the Log-rank test. SPSS for Windows 11 (SPSS Inc. 1981-2001, USA) and Microsoft Excel were used for all statistical calculations. The following pre-treatment variables were analysed for correlations with achievement of response, OS and PFS: age, gender, time of starting treatment and platelet count prior chemotherapy.
This study was based on 98 patients, their ages ranging from 11 to 65 years (median = 36). There were 56 males and 42 females. The median time from diagnosis to treatment was 14.3 weeks (range 0-239 weeks). Seventy-eight (80%) and 40 (41%) of 98 patients presented with splenomegaly and/ or hepatomegaly, with a median size of 12cm and 7cm below the costal margin, respectively; 85 (86.7%) patients were in CP and 13 (13.2%) in AP/BP (12 and 1 respectively, Table 1).
Table 1. Patients’ characteristics at diagnosis
With a median follow-up of 25 months, 51 patients had repeat chromosome analysis at least 6 months into Glivec therapy; 30 (59%) and 18 (35%) achieved CCR and a MCR, respectively.
Also notable was the fact that on completion of one and three months of Imatinib therapy, 53/83 (64%) and 58/70 (83%) of patients respectively were in complete haematologic remission (CHR).
Kaplan-Meier analysis of the relevant pre- and post-recruitment variables shows that commencement of Imatinib within 60 days of diagnosis, and achievement of CHR within one month of commencing therapy were predictive for achieving a CCR (p = 0.039 and 0.019 respectively; Table 2).
Table 2. Univariate analysis of patients characteristics, survival and cytogenetic remission.
p-Values in bold type are significant, those in regular type are close to significance. *The variables with the better outcomes are written first. Abbreviations: OS, overall survival; PFS, progression-free survival; SE, standard error; BCM, below the costal margin; LFU, last follow-up; ns, not significant; NA, not applicable; CHR, complete haematologic remission; CCR: complete cytogenetic remission; MCR: major cytogenetic remission; mCR: minor cytogenetic remission.
Kaplan-Meier estimates for OS and PFS at one year were 96% and 91%, respectively. At 40 months, the OS and PFS had dropped to 68% and 61%, respectively. Eighty-seven of the 98 patients overall (88.8%) remain alive, and are tolerating the drug well.
Also, achievement of CHR within 3 months or CCR within 6 months of commencing therapy predicted for better OS and PFS (CHR: p = 0.027, 0.011 respectively; CCR: p = 0.043, 0.045 respectively; Table 2). A statistically insignificant trend (p = 0.06) was observed for better OS in patients who did not experience myelosuppression (requiring cessation of the drug for ≥ 2 weeks) during the first 6 months of treatment. Eleven of the 44 patients (25%) who were in MCR/mnCR at six months had improved to CCR at the last follow-up.
With a median follow-up of 25 months, these results demonstrate a CCR rate of 59%, which is the same as that reported by Kantarjian et al in a previous study with 18 months' follow-up . The latter group of patients had however previously received IFN-α, whereas most of the Nigerian patients had been treated with hydroxyurea as first-line therapy. Overall, 80% of newly diagnosed patients with CML in chronic phase would be expected to achieve CCR with Imatinib . In this study, relatively shorter survival was to be expected, since 21 patients were not in chronic phase at the time of starting treatment, and responses are known to be less durable in AP and almost always transient in BP [8, 15, 16].
The median time from diagnosis to commencement of Imatinib was relatively long, at 14.3 weeks (range 0-239 weeks) and it is known that this can worsen the prognosis and reduce the probability of response. Nonetheless, the relatively high survival (96%, SE = 0.022) at one year is impressive for an African population of patients, although obviously, this value will fall with longer follow-up, with 68.3% at 40 months. The extended IRIS study has recently reported a 5-year overall survival estimate of 89%  and several studies have demonstrated significant survival differences based on the Sokal and/or Hasford risk groups at diagnosis [14, 15, 18-20]. However, these parameters could not be evaluated since initial data (at diagnosis) on the majority of our patients were unavailable.
The survival advantage observed for patients in whom CCR was achieved by six months is an important finding since it confirms the efficacy of Imatinib, an observation that has not been reported in native sub-Saharan Africans before. This pioneering work has shown that outcome of Imatinib therapy for Ph+ CML in native Nigerians is no different from reports in the Western populations.
We conclude that Imatinib in Nigerian patients with CML is very promising with the additional advantages of oral availability and tolerability, both of which make the drug highly acceptable.
We are grateful to Novartis for providing Imatinib mesylate (Glivec), to the Max Foundation and Axios International for facilitating the delivery of the drug, to the Federal Government and NAFDAC for facilitating customs clearance of the drug. We are also indebted to all the faculty and staff of the Department of Haematology, Obafemi Awolowo University (OAU) and OAU Teaching Hospitals Complex, Ile-Ife for the care of the patients involved in this study. We are especially grateful to the nursing staff. Professor Ama Rohatiner of the St. Baths Hospital, London, kindly reviewed the manuscript.
1. Deninger MWN, Druker BJ. Specific Targeted Therapy of Chronic Myelogenous Leukemia with Imatinib. Pharmacol Rev. 2003;55:401-423.
2. Boma PO, Durosinmi MA, Adediran IA, Akinola NO, Salawu L. Clinical and prognostic features of Nigerians with chronic myeloid leukemia. Niger Postgrad Med J. 2006;13:47-52.
3. Okanny CC, Akinyanju OO. Chronic leukaemia: an African experience. Med Oncol Tumor Pharmacother. 1989;6:189-194.
4. Fleming AF, Menendez C. Blood. In: Parry E, Godfrey R, Mabey D, Gill G, eds. Principles of Medicine in Africa. Vol. 78. Cambridge, United Kingdom; 2004:961.
5. Groves FD, Linet MS, Devesa SS. Patterns of occurrence of the leukaemias. Eur J Cancer. 1995;31A:941-994.
6. Deininger MWN, O'Brien SG, Ford JM, Druker BJ. Practical management of patients with chronic myeloid leukemia receiving Imatinib. J Clin Oncol. 2003;21:1637-1647.
7. Melo JV, Hughes TP, Apperley JF. Chronic myeloid leukemia. ASH Hematology. 2003:132-152.
8. Shah NP. Loss of Response to Imatinib: Mechanisms and Management. Hematology. 2005;2005:183-187.
9. Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL. Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor. Science. 2004;305:399-401.
10. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 2002;100:2292–2302.
11. Cortes JE, Talpaz M, O’Brien S, et al. Staging of Chronic Myeloid Leukemia in the Imatinib Era: An Evaluation of the World Health Organization Proposal. Cancer. 2006;106:1306–1315.
12. Baccarani M, Saglio G, Goldman J, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 2006;108:1809–1820.
13. Kantarjian H, Sawyers C, Hochhaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med. 2002;346:645-652.
14. Deininger MWN. Chronic myeloid leukemia: Management of Early Stage Disease. ASH Hematology. 2005:174-182.
15. Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science. 2001;293:876-880.
16. O'Brien S, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348:994-1008.
17. Talpaz M, Silver RT, Druker BJ, et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood. 2002;99:1928-1937.
18. Hasford J, Pfirrmann M, Hehlmann R, et al. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. J Natl Cancer Inst. 1998;90:850-858.
19. Sneed TB, Kantarjian HM, Talpaz M, et al. The Significance of Myelosuppression during Therapy with Imatinib Mesylate in Patients with Chronic Myelogenous Leukemia in Chronic Phase. Cancer. 2004;100:116–121.
20. Sokal JE, Cox EB, Baccarani M, et al. Prognostic Discrimination in “Good Risk” Chronic Granulocytic Leukemia. Blood. 1984;63:789-799.